SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-22-158000
Filing Date
2022-05-24
Accepted
2022-05-24 07:30:33
Documents
14
Period of Report
2022-05-24
Items
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d361499d8k.htm   iXBRL 8-K 23487
2 EX-99.1 d361499dex991.htm EX-99.1 15694
6 GRAPHIC g361499g93e05.jpg GRAPHIC 16681
  Complete submission text file 0001193125-22-158000.txt   189640

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA aeri-20220524.xsd EX-101.SCH 2869
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE aeri-20220524_lab.xml EX-101.LAB 17995
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE aeri-20220524_pre.xml EX-101.PRE 11270
8 EXTRACTED XBRL INSTANCE DOCUMENT d361499d8k_htm.xml XML 3404
Mailing Address 4301 EMPEROR BOULEVARD SUITE 400 DURHAM NC 27703
Business Address 4301 EMPEROR BOULEVARD SUITE 400 DURHAM NC 27703 (919) 237-5300
AERIE PHARMACEUTICALS INC (Filer) CIK: 0001337553 (see all company filings)

IRS No.: 203109565 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36152 | Film No.: 22954008
SIC: 2836 Biological Products, (No Diagnostic Substances)